Pulnovo Medical Limited, a globally recognized pioneer in medical device for pulmonary hypertension (PH) and heart failure (HF), is pleased to announce the successful first two commercial uses of its PADN products in Macau. This marks the entry of Pulnovo’s PADN products in Macau market. It reinforces Pulnovo Medical’s footprint in the Greater Bay Area following PADN products’ launch in Hong Kong. It brings the first disruptive treatment option to pulmonary hypertension patients in the regions, reinforcing Pulnovo Medical’s commitment to advancing cardiovascular health globally with cutting-edge technology.

Prior to the procedures, Kiang Wu Hospital convened an in-depth PADN multidisciplinary team (MDT) discussion comprising cardiologists, echocardiography specialists, rheumatologists, radiologists, and pediatricians. The session was focused on topics such as PADN’s mechanism of action, target selection, and case studies, ensuring an optimized treatment plan for the two patients undergoing the procedure.

Led by Professor Shaoliang Chen from Nanjing Medical University Affiliated Nanjing Hospital, the PADN procedures were performed by Professor Caojin Zhang from Guangdong Provincial People's Hospital, as well as Professor Guanchang Tan and his team at Kiang Wu Hospital. The operations were conducted smoothly, with the PADN products demonstrating exceptional efficacy with significant post-operative improvements in pulmonary hemodynamics. The patients showed promising recovery progress, offering renewed hope for pulmonary hypertension patients in Macau.